Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

NCT07243938 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Rectal Cancer (LARC)
Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Metastatic Colorectal Cancer (mCRC)
Neoadjuvant Therapy

Interventions

RADIATION: short-course radiotherapy
DRUG: Zanidatamab
DRUG: Tisleizumab(BGB-A317)
DRUG: Capecitabine
DRUG: Oxaliplatin
PROCEDURE: TME surgery
DRUG: S-1
PROCEDURE: D2

Sponsor

Tao Zhang